polymyxin B/bacitracin topical (OTC)

Treatment/Prophylaxis Superficial Skin Infection

Apply topically qD-TID

Other Information

For gram-pos & gram-neg infections

Good broad spectrum coverage

Does not cause allergic contact dermatitis like neosporin or other neomycin containing topical antibiotic preparations

Treatment/Prevention Superficial Skin Infection

Apply Topically qD-TID

Other Information

For gram-pos & gram-neg infections

Good broad spectrum coverage

Does not cause allergic contact dermatitis like neosporin or other neomycin containing topical antibiotic preparations

Contraindicated (1)

• allogeneic cultured keratinocytes/fibroblasts in bovine collagen

  polymyxin B decreases effects of allogeneic cultured keratinocytes/fibroblasts in bovine collagen by Other (see comment). Contraindicated. Comment: Exposure to topical antibiotics has been antibiotics shown to degrade Gintuit; if exposed, irrigate the wound thoroughly with saline and allow a suitable wash-out period to elapse before applying Gintuit.
  
  bacitracin topical decreases effects of allogeneic cultured keratinocytes/fibroblasts in bovine collagen by Other (see comment). Contraindicated. Comment: Exposure to topical antibiotics has been antibiotics shown to degrade Gintuit; if exposed, irrigate the wound thoroughly with saline and allow a suitable wash-out period to elapse before applying Gintuit.

Serious - Use Alternative (14)

• amphotericin B deoxycholate

  amphotericin B deoxycholate and polymyxin B both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug.

• atracurium

  polymyxin B increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• bacitracin

  polymyxin B and bacitracin both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Avoid concurrent use of bacitracin with other nephrotoxic drugs

• cholera vaccine

  polymyxin B, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.

• cidofovir

  cidofovir and polymyxin B both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug.

• cisatracurium

  polymyxin B increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• incobotulinumtoxinA

  polymyxin B increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• neomycin PO

  neomycin PO and polymyxin B both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug.

• onabotulinumtoxinA

  polymyxin B increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• pancuronium

  polymyxin B increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• rapacuronium

  polymyxin B increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• rocuronium

  polymyxin B increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• succinylcholine

  polymyxin B increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• vecuronium

  polymyxin B increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

Monitor Closely (19)

• acyclovir

  acyclovir and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• amikacin

  amikacin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• capreomycin

  capreomycin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• carboplatin

  carboplatin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• cephaloridine

  cephaloridine and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• cisplatin

  cisplatin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• colistin

  colistin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• contrast media (iodinated)

  contrast media (iodinated) and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• cyclosporine

  cyclosporine and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• elvitegravir/cobicistat/emtricitabine/tenofovir DF

  polymyxin B and elvitegravir/cobicistat/emtricitabine/tenofovir DF both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• gentamicin

  gentamicin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• ioversol

  ioversol and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• oxaliplatin

  oxaliplatin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• sodium picosulfate/magnesium oxide/anhydrous citric acid

  polymyxin B decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.

• streptozocin

  polymyxin B and streptozocin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• tacrolimus

  polymyxin B and tacrolimus both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• teicoplanin

  polymyxin B and teicoplanin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• tobramycin

  polymyxin B and tobramycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• voclosporin

  voclosporin, polymyxin B. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

Minor (9)

• adefovir

  adefovir and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• entecavir

  polymyxin B, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.

• foscarnet

  foscarnet and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• methoxyflurane

  methoxyflurane and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• paromomycin

  paromomycin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• pentamidine

  pentamidine and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• streptomycin

  polymyxin B and streptomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• vancomycin

  polymyxin B and vancomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• verteporfin

  polymyxin B increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown.

• acyclovir

  Monitor Closely (1)acyclovir and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• adefovir

  Minor (1)adefovir and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• allogeneic cultured keratinocytes/fibroblasts in bovine collagen

  Contraindicated (2)polymyxin B decreases effects of allogeneic cultured keratinocytes/fibroblasts in bovine collagen by Other (see comment). Contraindicated. Comment: Exposure to topical antibiotics has been antibiotics shown to degrade Gintuit; if exposed, irrigate the wound thoroughly with saline and allow a suitable wash-out period to elapse before applying Gintuit.
  
  bacitracin topical decreases effects of allogeneic cultured keratinocytes/fibroblasts in bovine collagen by Other (see comment). Contraindicated. Comment: Exposure to topical antibiotics has been antibiotics shown to degrade Gintuit; if exposed, irrigate the wound thoroughly with saline and allow a suitable wash-out period to elapse before applying Gintuit.

• amikacin

  Monitor Closely (1)amikacin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• amphotericin B deoxycholate

  Serious - Use Alternative (1)amphotericin B deoxycholate and polymyxin B both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug.

• atracurium

  Serious - Use Alternative (1)polymyxin B increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• bacitracin

  Serious - Use Alternative (1)polymyxin B and bacitracin both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Avoid concurrent use of bacitracin with other nephrotoxic drugs

• capreomycin

  Monitor Closely (1)capreomycin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• carboplatin

  Monitor Closely (1)carboplatin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• cephaloridine

  Monitor Closely (1)cephaloridine and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• cholera vaccine

  Serious - Use Alternative (1)polymyxin B, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.

• cidofovir

  Serious - Use Alternative (1)cidofovir and polymyxin B both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug.

• cisatracurium

  Serious - Use Alternative (1)polymyxin B increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• cisplatin

  Monitor Closely (1)cisplatin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• colistin

  Monitor Closely (1)colistin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• contrast media (iodinated)

  Monitor Closely (1)contrast media (iodinated) and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• cyclosporine

  Monitor Closely (1)cyclosporine and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• elvitegravir/cobicistat/emtricitabine/tenofovir DF

  Monitor Closely (1)polymyxin B and elvitegravir/cobicistat/emtricitabine/tenofovir DF both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• entecavir

  Minor (1)polymyxin B, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.

• foscarnet

  Minor (1)foscarnet and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• gentamicin

  Monitor Closely (1)gentamicin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• incobotulinumtoxinA

  Serious - Use Alternative (1)polymyxin B increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• ioversol

  Monitor Closely (1)ioversol and polymyxin B both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• methoxyflurane

  Minor (1)methoxyflurane and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• neomycin PO

  Serious - Use Alternative (1)neomycin PO and polymyxin B both increase nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug.

• onabotulinumtoxinA

  Serious - Use Alternative (1)polymyxin B increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• oxaliplatin

  Monitor Closely (1)oxaliplatin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• pancuronium

  Serious - Use Alternative (1)polymyxin B increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• paromomycin

  Minor (1)paromomycin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• pentamidine

  Minor (1)pentamidine and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• rapacuronium

  Serious - Use Alternative (1)polymyxin B increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• rocuronium

  Serious - Use Alternative (1)polymyxin B increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• sodium picosulfate/magnesium oxide/anhydrous citric acid

  Monitor Closely (1)polymyxin B decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.

• streptomycin

  Minor (1)polymyxin B and streptomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• streptozocin

  Monitor Closely (1)polymyxin B and streptozocin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• succinylcholine

  Serious - Use Alternative (1)polymyxin B increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• tacrolimus

  Monitor Closely (1)polymyxin B and tacrolimus both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• teicoplanin

  Monitor Closely (1)polymyxin B and teicoplanin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

• tobramycin

  Monitor Closely (1)polymyxin B and tobramycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

• vancomycin

  Minor (1)polymyxin B and vancomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

• vecuronium

  Serious - Use Alternative (1)polymyxin B increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression.

• verteporfin

  Minor (1)polymyxin B increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown.

• voclosporin

  Monitor Closely (1)voclosporin, polymyxin B. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.